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Abstract
Introduction A number of breast cancer risk prediction models
have been developed to provide insight into a woman's
individual breast cancer risk. Although circulating levels of
estradiol in postmenopausal women predict subsequent breast
cancer risk, whether the addition of estradiol levels adds
significantly to a model's predictive power has not previously
been evaluated.
Methods Using linear regression, the authors developed an
imputed estradiol score using measured estradiol levels (the
outcome) and both case status and risk factor data (for example,
body mass index) from a nested case-control study conducted
within a large prospective cohort study and used multiple
imputation methods to develop an overall risk model including
both risk factor data from the main cohort and estradiol levels
from the nested case-control study.
Results The authors evaluated the addition of imputed estradiol
level to the previously published Rosner and Colditz log-
incidence model for breast cancer risk prediction within the
larger Nurses' Health Study cohort. The follow-up was from
1980 to 2000; during this time, 1,559 invasive estrogen
receptor-positive breast cancer cases were confirmed. The
addition of imputed estradiol levels significantly improved risk
prediction; the age-specific concordance statistic increased
from 0.635 ± 0.007 to 0.645 ± 0.007 (P < 0.001) after the
addition of imputed estradiol.
Conclusion Circulating estradiol levels in postmenopausal
women appear to add to other lifestyle factors in predicting a
woman's individual risk of breast cancer.
Introduction
Breast cancer risk prediction models have been developed for
use as an entry criterion into breast cancer chemoprevention
trials (for example, National Surgical Adjuvant Breast and
Bowel Project tamoxifen trial and the Study of Tamoxifen and
Raloxifene), in counseling women on the potential use of che-
mopreventives, and to provide insight into a woman's individ-
ual breast cancer risk [1-4]. The initial Gail model incorporated
a subset of breast cancer risk factors, namely age, age at
menarche, age at first birth, family history of breast cancer or
of atypical hyperplasia, and history of breast biopsies [5,6].
Subsequently, several groups have developed more extensive
statistical models that incorporate a greater number of breast
cancer risk factors [1,4].
In postmenopausal women, circulating levels of estradiol pre-
dict subsequent breast cancer risk [7-10], particularly for
estrogen receptor (ER)-positive disease [9]. However, plasma
BBD = benign breast disease; BMI = body mass index; C statistic = concordance statistic; CI = confidence interval; ER = estrogen receptor; PMH 
= postmenopausal hormone; Q1, Q2, Q3, and Q4 = first, second, third, and fourth quartile; RR = relative risk.Breast Cancer Research    Vol 10 No 4    Rosner et al.
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estradiol levels have not previously been evaluated within risk
prediction models, and whether their addition would add to the
model's predictive power is unknown. Plasma estradiol is avail-
able only from the Nurses Health Study nested case-control
data set. We initially attempted to evaluate the addition of
estradiol concentrations to the Rosner and Colditz risk predic-
tion model using data from the Nurses' Health Study nested
case-control data set. However, with the relatively modest size
of the nested case-control data set and the large number of
parameters to be estimated, a number of the risk factor param-
eters did not adequately reflect those from the parent cohort.
Thus, development of an accurate risk prediction tool requires
a large sample size as in the main Nurses' Health Study cohort.
The purpose of this paper is to describe a methodology for
developing a risk prediction rule when one or more predictors
are incompletely observed and to apply it to assess the predic-
tive power of plasma estradiol after adjusting for standard
breast cancer risk factors as well as the effect of other risk fac-
tors adjusted for plasma estradiol.
Materials and methods
Cohort
The Nurses' Health Study cohort was established in 1976,
when 121,700 female US nurses (30 to 55 years old)
responded to a mailed questionnaire that inquired about repro-
ductive history and a range of lifestyle factors in addition to dis-
ease diagnoses [11,12]. Follow-up questionnaires have been
mailed biennially to update exposure information and any major
medical events. Deaths are reported by family members or the
postal service or are identified by a search of the National
Death Index. We estimate that mortality ascertainment is 98%
complete [13,14]. This investigation was approved by the
Brigham and Women's Hospital institutional review board.
Identification of breast cancer cases
On each questionnaire, we inquired whether breast cancer
had been diagnosed and, if so, the date of diagnosis. All
women who reported breast cancer (or the next of kin for
decedents) were contacted for permission to review medical
records to confirm the diagnosis. We include only invasive
cases of breast cancer confirmed by the pathology report. ER
and progesterone receptor status of the tumor was deter-
mined from the medical record. In this report, we evaluate ER+
cases only, as we previously observed that plasma estradiol
most strongly predicted this tumor subtype [9].
Population for analysis
The population of women used in this analysis has been
described in detail in several previous publications [1,15].
Briefly, we excluded women with unknown, inconsistent, or
out-of-range reports for height, weight in 1976 or at age 18,
age at menarche or menopause or each pregnancy, parity, and
duration or type of postmenopausal hormone (PMH) use (n =
42,886). Additionally, women with a simple hysterectomy (and
hence unknown age at menopause) (n = 10,301) were
excluded. Participants who were ineligible for the study (for
example, prevalent cancer in 1976) or no follow-up after 1978
(n = 2,360) were excluded. In the current analysis, women
who were premenopausal throughout follow-up were
excluded (n = 6,342), but once they became postmenopausal,
they could contribute person-time. Overall, 59,812 partici-
pants remained for this analysis. These women contributed
750,086 person-years from 1980 to 2000, during which
1,559 incident invasive ER+ breast cancer cases occurred.
Blood subcohort and nested case-control study
From 1989 to 1990, 32,826 cohort members provided blood
samples. Informed consent was obtained from each partici-
pant; details about the blood collection methods have been
published previously [16,17]. Briefly, women arranged to have
their blood drawn and shipped with an icepack via overnight
courier to our laboratory, where it was processed and archived
in liquid nitrogen freezers. Estradiol is stable in cooled whole
blood for 24 to 48 hours [18]. At blood collection, women
completed a short questionnaire that included questions on
recent use of PMH (within the last 3 months). Follow-up of the
blood study cohort was 99% in 2000.
In the current analyses, we used a previously described nested
case-control study of sex steroids and breast cancer risk with
cases diagnosed after blood collection through 31 May 1998
[9,16]. In addition, cases diagnosed up through 31 May 2000
and their matched controls (that is, a 2-year extension of the
published report [9]) are included. At blood collection, cases
and controls were postmenopausal, were not recent users of
PMH, and had no prior diagnosed cancer (except non-
melanoma skin cancer). Control subjects were matched by
age, month/year and time of day of blood collection, and fast-
ing status and had not been diagnosed with breast cancer
before the diagnosis date of their matched case. To mimic the
larger population used in the risk prediction modeling, only
cases and controls meeting the inclusion criteria described
above were included (for example, no prior simple hysterec-
tomy). Women were considered postmenopausal if they
reported having a natural menopause (for example, no men-
strual cycles during the previous 12 months) or had a bilateral
oophorectomy. In all, 164ER+ cases and 346 controls were
included.
Laboratory assays
Estradiol was measured by radioimmunoassay following
extraction and celite column chromatography, as previously
described [9]. The coefficient of variation was less than or
equal to 11%.
Description of the risk prediction model
We fit the log-incidence model of breast cancer to incident
ER+cases, as previously described [1,15]. We assume that
incidence at time, t(It), is proportional to the number of cell divi-
sions, Ct, accumulated throughout life up to age t; that is,Available online http://breast-cancer-research.com/content/10/4/R55
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It = kCt
The cumulative number of breast cell divisions is factored as
follows:
Thus, λi = Ci+1/Ci represents the rate of increase of breast cell
divisions from age i to age i+1. Log (λi) is assumed to be a lin-
ear function of risk factors that are relevant at age i. The set of
risk factors and their magnitude may vary according to the
stage of reproductive life. Details of the representation of the
Ci are given in [1,15]. The overall model is given by:
t = age
to = age at menarche
tm = age at menopause
st = parity at age t
ti = age at ith birth, i = 1, ..., st
b = birth index =   for parous women, = 0 for
nulliparous women
bit = 1 if parity is greater than or equal to i at age t (otherwise,
bit = 0)
mA = 1 if natural menopause (otherwise, mA = 0)
mB = 1 if bilateral oophorectomy (otherwise,mB = 0)
bbd = 1 if breast disease is benign (otherwise, bbd = 0)
fhx = 1 if there is a family history of breast cancer in mother or
sister (otherwise, fhx = 0)
pmhA = number of years on oral estrogen
pmhB = number of years on oral estrogen and progestin
pmhC = number of years on other types of PMHs
pmhcur,t = 1 if current user of postmenopausal hormones at
age t (otherwise, pmhcur,t = 0)
pmhpast,t = 1 if past user of postmenopausal hormones at age
t (otherwise, pmhpast,t = 0)
BMIj = body mass index (BMI) at age j (kg/m2)
alcj = alcohol consumption (grams) at age j
h = height (inches)
The general rationale for a log-incidence model is that the
number of precancerous cells increases multiplicatively with
time but that historical exposures differentially affect the rate of
increase. Specifically, for breast cancer, the number of pre-
cancerous cells is assumed to increase annually at the rate of
exp(β0) prior to menopause for nulliparous women, at the rate
of exp(β0 + β1s) prior to menopause for parous women with
parity = s, and so forth. Finally, the number of precancerous
cells increases immediately after the first birth by exp [β2(t1 -
t0)]. The incidence rate of breast cancer is assumed to be
approximately proportional to the number of precancerous
cells.
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The log-incidence model was fit using iteratively reweighted
least squares with PROC NLIN in SAS (SAS version 6.12;
SAS Institute Inc., Cary, NC, USA) (1996). The parameters of
the model are readily interpretable in a relative risk (RR) con-
text. For example, exp(-β0) = RR for a 1-year increase in age at
menarche among nulliparous women, exp [-(β0 + β2)] = RR for
a 1-year increase in age at menarche among parous women,
and so forth. In this analysis, women were followed until they
had an event (ER+ breast cancer) or were censored if they
developed (a) ER- breast cancer, (b) breast cancer in which
ER status is unknown, or (c) other types of cancer except non-
melanoma skin cancer or (d) if they died.
Imputation and inclusion of estradiol in the risk 
prediction model
Ideally, we would have estradiol levels measured on each main
study participant at several points in time. However, since this
was not possible, we used an indirect approach to impute
estradiol. Let x = estradiol and z = other covariates in the risk
prediction model.
From the main study, we can obtain Pr(D|z) given under the
rare disease assumption by:
We want to estimate Pr(D|x,z), where under the rare disease
assumption
Pr(D|x,z) ≅ exp(α* + β*z + δ*x).
From the blood study, we can estimate δ* based on condi-
tional logistic regression. Indeed, in principle, we could also
estimate β* from the blood study, but the estimates will be very
imprecise due to the small sample size. Therefore, we used the
main study population to estimate the parameters in Equation
5 by estimating x for all subjects in the main study based on a
linear regression derived from the blood study:
x = αo + γoy + γzimp + e,
where x = n (estradiol) as a continuous variable, y = 1 if case
and 0 if control, and Zimp = a subset of the other covariates Z
in the risk prediction model. Zimp was ascertained by first forc-
ing in y and then using stepwise-up regression to determine
the subset of components of Z in the main study which were
significantly associated with x at the 5% level.
In the blood study, estradiol levels on average were higher for
cases than controls. The rationale for including y as a covariate
in Equation 6 is to account for this relationship in the main
study as well. In addition, because there is substantial overlap
between the estradiol distribution of cases and controls, we
used an imputation strategy to estimate x by adding error to
the prediction such that for each main study participant we
obtain
where (a) ei = an error term that is normally distributed with
mean 0 and variance σ2, (b) yi = 1 if a breast cancer case and
= 0 otherwise, (c) σ2 is estimated from Equation 6, and e is
obtained by the RANNOR function of SAS so as to add error
to the estimate of x for individual women. We then fit the model
in Equation 5 using   instead of x, thus obtaining the model
Since the parameter estimates in Equation 8 may be influ-
enced by the random error introduced in Equation 7, we
repeated this imputation approach four additional times and
used multiple imputation [19] to combine estimates from the
separate imputations to obtain an overall estimate.
To assess the additional predictive power of serum estradiol,
we computed age-specific (5-year age groups) deciles of the
risk function without estradiol (model A) as well as including
imputed estradiol (model B). From the cross-classification of
risk decile model A × risk decile model B, we then compared
the observed number of cases in specific risk deciles of model
B with the expected number of cases within strata defined by
model A risk decile. Specifically, let Xij = the number of breast
cancer cases, Nij = the number of person-years, and pij = Xij/
Nij, which is the estimated incidence rate within the ith age-
specific risk decile for model A and the jth age-specific risk
decile for model B, and let ln(pij) = αi + β(j - 1). 100% ×
[exp( )-1] is an estimate of the percentage increase in breast
cancer incidence for an increase of one model B risk decile,
holding the model A risk decile constant [20]. We wish to test
the hypothesis H0: β = 0 versus H1: β ≠ 0. This approach of
cross-classifying individuals by two different risk prediction
rules is similar to the reclassification table approach used to
compare risk prediction rules in the Framingham Heart Study
[21]. In addition, to assess the predictive ability of our risk pre-
diction models, we used the area under the receiver operating
characteristic curve (that is, the concordance or C statistic).
This statistic ranges from 0.5 to 1.0 and represents the prob-
ability that, for a randomly selected pair of women, one with
ER+ breast cancer and one without breast cancer, the woman
with ER+ breast cancer has the higher estimated disease prob-
ability. Also, we compared the C statistic for different risk pre-
diction rules [22]. In our primary analysis, we evaluated the
addition of imputed estradiol levels to risk prediction models in
the entire cohort. As a secondary approach, we calculated
Rosner and Colditz model risk scores in the entire cohort and
then, in the nested case-control data set, assessed the impact
Pr (D |z) exp( z) / [ 1e x p ( z ) ] =++ αβ αβ αβ +≅ + exp( ).
 
z
ˆ
,
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of adding this score to the plasma estradiol and breast cancer
model.
Results
Within the nested case-control data set, we observed a signif-
icant association between plasma estradiol and risk of breast
cancer (Ptrend < 0.001), with an RR for the top (Q4) versus bot-
tom (Q1) quartile category of 3.3 (95% confidence interval
[CI] = 1.8 to 6.0) for ER+ breast cancer (Table 1). Each of the
variables in the Rosner and Colditz risk prediction model was
considered as a potential predictor of plasma estradiol. BMI
was most strongly related to estradiol level; in addition, the
birth index, case status, and duration of postmenopause each
contributed modestly but significantly (Table 2). Other varia-
bles, including family history of breast cancer, alcohol intake,
and history of BBD, did not contribute significantly to the
model and thus were dropped from further consideration. The
r2, for the regression model, was 0.219.
Most variables in the Rosner and Colditz model incorporate a
time component (for example, postmenopausal BMI = average
BMI postmenopause × duration postmenopause). Because
exposure status at the time of blood draw might be most
strongly correlated with estradiol, we also evaluated each of
the variables at the time of blood draw or, for variables ascer-
tained only on the main study questionnaire (for example, alco-
hol intake), within 2 years of blood draw. All results were
similar.
In Table 3, we present the standard risk prediction model with-
out estradiol and an enhanced model with imputed estradiol
based on an average of five imputations. The regression coef-
ficient for loge estradiol varied over the five imputations (0.400
to 0.582) with an average of 0.477. For a one-unit increase in
loge estradiol, the RR was 1.61 (95% CI = 1.35 to 1.93). Its
inclusion also caused changes in some of the other model
parameters. As expected, the regression coefficient for post-
menopausal BMI decreased from 0.0038 (P  < 0.001) to
0.0023 (P = 0.002). For example, if we compare two 70-year-
old postmenopausal women with age at menopause of 50
years, no PMH use, and constant BMI of 20 and 30, respec-
tively, from age 50 to 70, then the RRs of breast cancer at age
70 for the woman with BMI = 30 versus the woman with BMI
= 20 would be exp(0.0038 × 10 × 20) = 2.1 (95% CI = 1.7
to 2.7) without controlling for estradiol and exp(0.0023 × 10
× 20) = 1.6 (95% CI = 1.2 to 2.1) after controlling for estra-
diol. Also, the regression coefficient for the birth index
decreased from -0.0030 ± 0.0007 (P < 0.001) to -0.0020 ±
0.0008 (P = 0.02). To interpret this difference, we compare
two postmenopausal women with age at menarche of 13 and
age at menopause of 50, one of whom had four births at ages
20, 23, 26, and 29 whereas the other was nulliparous. The
birth indices for these two women are 102 [(50 - 20) + (50 -
23) + (50 - 26) + (50 - 29)] and 0, respectively. The RRs for
the parous versus nulliparous woman are exp [-0.0030(102)]
= 0.74 (95% CI = 0.64 to 0.85) without and exp [-
0.0020(102)] = 0.82 (95% CI = 0.69 to 0.96) with controlling
for loge estradiol. Finally, the regression coefficient for both the
duration after natural menopause and the duration after bilat-
eral oophorectomy increased after adjusting for loge estradiol.
To interpret this finding, we compare two postmenopausal
women with age at natural menopause of 45 and 55 years,
respectively. The RRs of breast cancer for the second com-
pared with the first woman are exp [10(0.102-0.049)] = 1.7
(95% CI = 1.4 to 2.0) without and exp [10(0.101-0.056)] =
1.6 (95% CI = 1.3 to 1.9) with adjusting for loge estradiol. It
appears that part of the effect of BMI, parity, and late meno-
pause on the incidence of breast cancer is mediated in part by
changes in loge estradiol caused by obesity (increase), multi-
parity with first birth at an early age (decrease), and delayed
menopause (increase), respectively.
We now present the cross-classification of model A × model
B risk decile in Table 4. It is clear from Table 4 that, within most
model A risk deciles, there are important differences in esti-
mated incidence according to model B risk decile (often two-
fold). Overall, for a given model A risk decile, the observed
number of cases was higher than expected when the model B
decile was high and lower than expected when the model B
decile was low. The overall slope was β = 0.511 ± 0.034 (P <
Table 1
Relative risk of estrogen receptor-positive breast cancer by quartile of postmenopausal plasma estradiol concentration (164 cases 
and 346 controls)a
Quartile of plasma estradiol
12 3 4 P for trend
Relative risk 1 1.6 1.4 3.3
95% confidence interval 0.9–2.9 0.8–2.7 1.8–6.0 <0.001
aUnconditional logistic regression controlling for matching factors (age, month and time of day of blood collection, and fasting status) and duration 
of premenopause, duration of menopause (separately for natural menopause and bilateral oophorectomy), birth index, age at first birth minus age 
at menarche, benign breast disease, duration of estrogen use, duration of estrogen and progestin use, duration of use of other types of 
postmenopausal hormones (PMH), current PMH use, past PMH use, average body mass index before and after menopause, and family history of 
breast cancer.Breast Cancer Research    Vol 10 No 4    Rosner et al.
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0.001), indicating that there is a significant estimated 67%
increase in breast cancer incidence for an increase of one
model B age-specific risk decile, holding the age-specific
model A risk decile constant. This indicated that there is sub-
stantial increased predictive power upon adding loge estradiol
to the risk prediction model.
In addition, we compared the age-specific C statistics
between model A versus model B. We found C statistics of
0.635 ± 0.007 for model A and 0.645 ± 0.007 for model B (C
statistic model A versus C statistic model B; P < 0.001). Using
our secondary approach (applying the population-based risk
scores to the subset of women in the nested case-control
study), the RRs of breast cancer by plasma hormone level
were similar, though slightly attenuated, compared with those
in Table 1. For example, the RRs of ER+ breast cancer with
increasing quartile of estradiol were 1.0, 1.5, 1.4, and 2.5
(95% CI = 1.5 to 4.2). Finally, in Table 5, we present the 5-year
incidence of breast cancer by age and model B risk decile
after adjusting for competing mortality risks [23]. The RR of
breast cancer comparing women at the highest versus the
lowest age-specific decile ranges from 5.0 to 8.5. For exam-
ple, for 60- to 64-year-old women, the absolute 5-year risk of
breast cancer is 436/105(0.4%) for women in the first decile
and 2,982/105 (3.0%) for women in the 10th decile (RR =
6.8), indicating substantial differences in absolute risk accord-
ing to the model B risk equation.
Discussion
In the Nurses' Health Study, we found that estradiol levels, as
imputed from a nested case-control study within the same
cohort, added significantly to the Rosner and Colditz risk pre-
diction model, which already includes most confirmed breast
cancer risk factors. There was an increase of 67% in incidence
per increase of one model B risk decile, holding model A risk
decile constant. The increase in the C statistic was also statis-
tically significant.
Strengths of this study include the large size of the cohort and
the large number of available questionnaire-based breast can-
cer risk factors. Additionally, prospectively assessed estradiol
levels were available in a subset of the same women. Through
the use of both risk factors and case status in the linear regres-
sion, our imputed values as applied to the larger cohort
accounted for both the association between hormone level
and breast cancer and the correlation between hormone levels
and other risk factors already in the risk prediction model.
One limitation of the study was that we did not have measured
estradiol levels on all cohort members; however, this is a limi-
tation of all large prospective studies because of the high cost
of the assays. In addition, due to our desire to have consistent
eligibility criteria throughout, only 164 cases and 346 controls
in the nested case-control study met all criteria for the model
(for example, known age at menopause). Thus, it was not pos-
sible within this small data set to provide a sufficiently precise
evaluation of the Rosner and Colditz model (which contains 22
beta coefficients); in our initial attempt to evaluate the model,
all beta coefficients had wide CIs. In our secondary analyses,
in which we used the risk score within the nested case-control
data set, plasma estradiol again contributed significantly to the
model. However, the RR for estradiol in the secondary analysis
for Q4 versus Q1 was 2.5 (95% CI = 1.5 to 4.2) when con-
trolling for other risk factors using the Rosner-Colditz risk
scores versus 3.3 (95% CI = 1.8 to 6.0) when individual risk
factors were used within the case-control study. One would
expect that the effects of other risk factors are more accurately
measured by a single risk score derived from a large cohort
study than individual risk factors derived from a relatively small
nested case-control data set. More generally, this may indicate
better control for confounding in small case-control studies
Table 2
Imputation of log estradiol using data from the Nurses' Health Study breast cancer nested case-control studya
Variable Beta Standard error P value
Intercept 2.241 0.085
Case status 0.130 0.048 0.008
Body mass index (postmenopausal)b 0.0033 0.0003 <0.001
Birth indexc -0.0021 0.0006 <0.001
Duration of natural menopause -0.015 0.004 <0.001
Duration of menopause after bilateral oophorectomy -0.013 0.004 0.004
R2 = 0.219
aBased on 164 cases and 346 controls. bDuration postmenopause × average body mass index postmenopause. cBirth index =   
if parous and = 0 if nulliparous where s = parity; ti = age at ith birth, i = 1, ..., s; tm = age at menopause; and bit = 1 if parity is greater than or equal 
to i at age t and = 0 otherwise.
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Table 3
Risk prediction model for breast cancer with and without estradiol (loge)
No estradiol model
Parameter Beta SE P value Increment RR 95% CI
Intercept -10.8
Duration of premenopause, years 0.102 0.009 <0.001 1 1.11 1.09, 1.13
(Age at first birth minus age at menarche) × parousa 0.0035 0.0051 0.49 10 1.04 0.94, 1.14
Birth indexa -0.0030 0.0007 <0.001 102 0.74 0.64, 0.85
Duration of postmenopause (natural menopause) 0.049 0.006 <0.001 1 1.05 1.04, 1.06
Duration of postmenopause (bilateral oophorectomy) 0.039 0.008 <0.001 1 1.04 1.02, 1.06
Benign breast disease 0.288 0.656 0.66 1 1.33 0.37, 4.82
Benign breast disease × age at menarche 0.091 0.027 0.001 1 1.10 1.04, 1.15
Benign breast disease × duration premenopause -0.018 0.012 0.14 1 0.98 0.96, 1.01
Benign breast disease × duration postmenopause -0.029 0.008 <0.001 1 0.97 0.96, 0.99
Duration of estrogen use 0.032 0.008 <0.001 10 1.38 1.18, 1.61
Duration of estrogen plus progestin use 0.068 0.013 <0.001 10 1.97 1.53, 2.55
Duration of other PMH use 0.032 0.011 0.006 10 1.38 1.11, 1.71
Current PMH use 0.109 0.079 0.17 1 1.12 0.96, 1.30
Past PMH use -0.022 0.073 0.76 1 0.98 0.85, 1.13
Average BMI premenopause or postmenopause while on PMH × 
(duration premenopause + duration postmenopause while on PMH)
-0.0011 0.0003 <0.001 370b 0.67 0.54, 0.83
Average BMI postmenopause while not on PMH × 
(duration postmenopause while not on PMH)
0.0038 0.0006 <0.001 200c 2.14 1.69, 2.71
Height × (duration premenopause + duration postmenopause while on PMH) 0.00072 0.00037 0.052 222d 1.17 1.00, 1.38
Height × (duration postmenopause while not on PMH) -1 × 10-5 0.0015 0.99 120e 1.00 0.70, 1.42
Cumulative alcohol consumption before menopause, grams 0.00034 0.00009 <0.001 384f 1.14 1.06, 1.22
Cumulative alcohol consumption after menopause while on PMH -0.00036 0.00041 0.39 120g 0.96 0.87, 1.05
Cumulative alcohol consumption postmenopause while not on PMH 0.00008 0.00031 0.80 240h 1.02 0.88, 1.18
Family history of breast cancer 0.447 0.065 <0.001 1 1.56 1.38, 1.78
Model including loge estradioli
Parameter Beta SE P value Increment RR 95% CI
Intercept -11.9
Duration of premenopause, years 0.101 0.01 <0.001 1 1.11 1.08, 1.13
(Age at first birth minus age at menarche) × parousa 0.0035 0.0055 <0.001 10 1.04 0.93, 1.15
Birth index -0.0020 0.0008 0.02 102 0.82 0.69, 0.96
Duration of postmenopause (natural menopause) 0.056 0.007 <0.001 1 1.06 1.04, 1.07
Duration of postmenopause (bilateral oophorectomy) 0.045 0.009 <0.001 1 1.05 1.03, 1.06
Benign breast disease 0.287 0.719 0.69 1 1.33 0.33, 5.45
Benign breast disease × age at menarche 0.091 0.029 0.002 1 1.10 1.03, 1.16
Benign breast disease × duration premenopause -0.018 0.014 0.18 1 0.98 0.96, 1.01
Benign breast disease × duration postmenopause -0.029 0.008 0.001 1 0.97 0.96, 0.99Breast Cancer Research    Vol 10 No 4    Rosner et al.
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based on risk scores derived from large cohorts versus internal
control for confounding based on individual risk factors whose
regression coefficients are poorly estimated in small case-con-
trol studies. With further follow-up and within a collaboration
across several cohorts at other institutions, we plan to re-eval-
uate the case-control approach.
In imputing estradiol levels, only BMI, the birth index, and dura-
tion of postmenopause (in addition to case status) were signif-
icant predictors of loge (estradiol). The correlation between
BMI and estradiol was expected given that aromatization of
androgens to estrogens in postmenopausal women occurs in
adipose tissue [24]. The association with the birth index, a
summary variable representing the number and spacing of
pregnancies, has been evaluated less frequently and data are
not as consistent [25-28]. The association with duration of
postmenopause may be due to declines in estrogen after men-
opause. Alcohol intake, which previously has been found to
correlate with estrogen levels in several studies [29], did not
contribute significantly here, which is consistent with our pre-
vious report from a subset of the current population showing
no correlation with estradiol [17]. To our knowledge, no other
lifestyle factors have consistently been shown to predict post-
menopausal estradiol levels. The correlation between meas-
ured and imputed estradiol was 0.47.
With the inclusion of imputed estradiol, the C statistic
increased from 0.635 to 0.645, which is a modest improve-
ment but suggests reasonable discriminatory ability overall.
However, the reclassification table approach (Table 4) indi-
cated that a substantial difference in incidence is explained by
including imputed estradiol, suggesting that the C statistic
may be relatively insensitive to additions of single predictors to
risk prediction models [21,30]. However, the relationship of
one or a combination of risk factors with disease must be very
strong – RRs on the order of 100 to 200 between exposed
and unexposed – to serve as a screening tool at the individual
level [31-33]. Continued expansion of current models with
other risk factors (for example, genetic factors, mammographic
density, or cytology from nipple aspirate fluid [34]) may further
improve the C statistic. In addition, if chemopreventive agents
were developed with few risks (and an acceptable cost-benefit
ratio), the need to minimize the false-positive rate would
decrease, similar to the use of cholesterol-lowering agents for
the prevention of heart disease.
Duration of estrogen use 0.032 0.009 <0.001 10 1.38 1.15, 1.64
Duration of estrogen plus progestin use 0.068 0.014 <0.001 10 1.97 1.50, 2.60
Duration of other PMH use 0.032 0.013 0.012 10 1.38 1.07, 1.78
Current PMH use 0.110 0.087 0.21 1 1.12 0.94, 1.32
Past PMH use -0.022 0.080 0.78 1 0.98 0.84, 1.14
Average BMI premenopause or postmenopause while on PMH × 
(duration premenopause + duration postmenopause while on PMH)
-0.0011 0.0003 <0.001 370b 0.67 0.54, 0.83
Average BMI postmenopause while not on PMH × 
(duration postmenopause while not on PMH)
0.0023 0.0007 0.002 200c 1.58 1.20, 2.08
Height × (duration premenopause + duration postmenopause while on PMH) 0.00072 0.00041 0.072 222d 1.17 0.98, 1.40
Height × (duration postmenopause while not on PMH) 0 0.0016 1 120e 1.00 0.69, 1.46
Cumulative alcohol consumption before menopause, grams 0.00034 0.0001 0.001 384f 1.14 1.06, 1.23
Cumulative alcohol consumption after menopause while on PMH -0.00036 0.00045 0.43 120g 0.96 0.86, 1.06
Cumulative alcohol consumption postmenopause while not on PMH 0.00008 0.00034 0.81 240h 1.02 0.87, 1.20
Family history of breast cancer 0.446 0.072 <0.001 1 1.56 1.36, 1.80
Loge estradiol 0.477 0.092 <0.001 1 1.61 1.35, 1.93
a0 for nulliparous women.
bComparing BMI = 20 versus BMI = 30 for 37 premenopausal years (age at menarche = 13, age at menopause = 50).
cComparing BMI = 20 versus BMI = 30 for 20 postmenopausal years (age at menopause = 50, age = 70).
dComparing height = 61 inches versus height = 67 inches for 37 premenopausal years (age at menarche = 13, age at menopause = 50).
eComparing height = 61 inches versus height = 67 inches for 20 postmenopausal years (age at menopause = 50, age = 70).
fComparing 1 drink per day (12 g) versus no intake for 32 premenopausal years (from age 18 to age 50).
gComparing 1 drink per day (12 g) versus no intake for 10 years of PMH use.
hComparing 1 drink per day (12 g) versus no intake for 20 postmenopausal years (age at menopause = 50, age = 70).
iBased on an average of five imputations.
BMI, body mass index; CI, confidence interval; PMH, postmenopausal hormone; RR, relative risk; SE, standard error.
Table 3 (Continued)
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Conclusion
In summary, our data indicate that circulating estradiol levels in
postmenopausal women may contribute significantly to cur-
rent risk prediction models. Further assessment of estradiol in
other studies and of other biomarkers that predict risk is
needed to continue to improve our ability to predict breast
cancer risk and inform prevention strategies. Similar
approaches can be used to incorporate other breast cancer
biomarkers in overall risk prediction models.
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Table 4
Cross-classification of model A risk decilea × model B risk decileb
Model B risk decile
123456789 1 0 S l o p e S E P value
Model A 
risk decile
Cases/py Cases/py Cases/py Cases/py Cases/py Cases/py Cases/py Cases/py Cases/py Cases/py
(Rate) (Rate) (Rate) (Rate) (Rate) (Rate) (Rate) (Rate) (Rate) (Rate)
1 41/
61,883
13/
12,253
0/756 0/20 0/2 0/0 0/0 0/0 0/0 0/0 0.471 0.318 0.14
(66) (106) (0) (0) (0) (-) (-) (-) (-) (-)
2 9/12,317 34/
42,222
36/
17,656
7/2,535 1/187 0/6 0/0 0/0 0/0 0/0 0.593 0.129 <0.001
(73) (81) (204) (276) (535) (0) (-) (-) (-) (-)
3 0/694 9/17,749 46/
34,208
31/
18,339
8/3,678 1/241 0/8 0/0 0/0 0/0 0.396 0.126 0.002
(0) (51) (134) (169) (218) (415) (0) (-) (-) (-)
4 0/18 1/2,567 18/
18,588
42/
31,754
43/
18,223
13/3,547 1/217 0/6 0/0 0/0 0.48 0.102 <0.001
(0) (39) (97) (132) (236) (367) (461) (0) (-) (-)
5 0/0 0/132 5/3,477 13/
18,417
47/
31,547
50/
18,268
18/3,010 2/158 0/0 0/0 0.565 0.085 <0.001
(-) (0) (144) (71) (149) (274) (598) (1,000) (-) (-)
6 0/0 0/2 1/231 3/3,635 21/
18,333
50/
32,782
54/
17,504
13/2,363 0/70 0/0 0.469 0.088 <0.001
(-) (0) (433) (83) (68) (153) (309) (550) (0) (-)
7 0/0 0/0 0/2 0/210 2/2,922 22/
17,752
76/
35,260
46/
17,428
9/1,351 0/0 0.44 0.099 <0.001
(-) (-) (0) (0) (68) (124) (216) (264) (666) (-)
8 0/0 0/0 0/0 0/10 0/116 4/2,272 31/
17,599
87/
35,817
79/
16,063
1/339 0.5 0.091 <0.001
(-) (-) (-) (0) (0) (176) (176) (226) (492) (295)
9 0/0 0/0 0/0 0/0 0/0 0/52 4/1,326 25/
16,137
140/
46,314
65/
11,093
0.553 0.099 <0.001
(-) (-) (-) (-) (-) (0) (302) (155) (302) (586)
10 0/0 0/0 0/0 0/0 0/0 0/0 0/0 1/305 21/
11,127
315/
63,483
0.841 0.207 <0.001
(-) (-) (-) (-) (-) (-) (-) (328) (189) (496)
Overall 0.511 0.034 <0.001
aModel A, standard risk prediction model without estradiol. bModel B, standard risk prediction model plus imputed estradiol. py, person-years; SE, standard error.Breast Cancer Research    Vol 10 No 4    Rosner et al.
Page 10 of 11
(page number not for citation purposes)
Acknowledgements
Support for this project was provided by National Institutes of Health 
grants P01 CA87969, CA49449, and CA089393 (Specialized Pro-
grams of Research Excellence in Breast Cancer). GAC was supported 
in part by a clinical research professorship from the American Cancer 
Society. We acknowledge Marion McPhee for programming assistance 
and Jessica Bugg for preparation assistance.
References
1. Colditz GA, Rosner B: Cumulative risk of breast cancer to age
70 years according to risk factor status: data from the Nurses'
Health Study.  Am J Epidemiol 2000, 152:950-964.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah
M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M,
Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for pre-
vention of breast cancer: report of the National Surgical Adju-
vant Breast and Bowel Project P-1 Study.  J Natl Cancer Inst
1998, 90:1371-1388.
3. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Bal-
lard-Barbash R, Pfeiffer RM: Cancer risk prediction models: a
workshop on development, evaluation, and application.  J Natl
Cancer Inst 2005, 97:715-723.
4. Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model
incorporating familial and personal risk factors.  Stat Med
2004, 23:1111-1130.
5. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Beni-
chou J, Wieand HS: Validation studies for models projecting
the risk of invasive and total breast cancer incidence.  J Natl
Cancer Inst 1999, 91:1541-1548.
6. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzl-
souer K, Vogel V: Weighing the risks and benefits of tamoxifen
treatment for preventing breast cancer.  J Natl Cancer Inst
1999, 91:1829-1846.
7. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dos-
sus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-
Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH,
Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiébaut
A, González CA, Quirós JR, Tormo MJ, Ardanaz E, Amiano P,
Krogh V, Palli D, Panico S, Tumino R, et al.: Postmenopausal
serum androgens, oestrogens and breast cancer risk: the
European prospective investigation into cancer and nutrition.
Endocr Relat Cancer 2005, 12:1071-1082.
8. Key T, Appleby P, Barnes I, Reeves G: Endogenous sex hor-
mones and breast cancer in postmenopausal women: reanal-
ysis of nine prospective studies.  J Natl Cancer Inst 2002,
94:606-616.
9. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE: Endog-
enous estrogen, androgen, and progesterone concentrations
and breast cancer risk among postmenopausal women.  J Natl
Cancer Inst 2004, 96:1856-1865.
10. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A,
Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P: Post-
menopausal levels of oestrogen, androgen, and SHBG and
breast cancer: long-term results of a prospective study.  Br J
Cancer 2004, 90:153-159.
Table 5
Five-year risk of breast cancer by age and model B risk decile
Model B risk decile
A g e  g r o u p ,  y e a r s 1 23456789 1 0
30–34 5-year incidencea 65 73 82 97 105 127 147 197 249 321
RR 1 1.1 1.3 1.5 1.6 2.0 2.3 3.0 3.8 5.0
35–39 5-year incidencea 82 107 126 142 160 182 214 259 328 504
RR 1 1.3 1.5 1.7 2.0 2.2 2.6 3.1 4.0 6.1
40–44 5-year incidencea 117 159 191 221 253 294 350 425 527 767
RR 1 1.4 1.6 1.9 2.1 2.5 3.0 3.6 4.5 6.6
45–49 5-year incidencea 177 249 299 347 401 467 550 659 823 1,231
RR 1 1.4 1.7 2.0 2.7 2.6 3.1 3.7 4.6 7.0
50–54 5-year incidencea 266 373 447 522 605 702 819 973 1,204 1,824
RR 1 1.4 1.7 2.0 2.3 2.6 3.1 3.7 4.5 6.9
55–59 5-year incidencea 351 495 595 692 795 913 1,057 1,247 1,542 2,368
RR 1 1.4 1.7 2.0 2.3 2.6 3.0 3.6 4.4 6.7
60–64 5-year incidencea 436 630 759 881 1,009 1,151 1,323 1,548 1,909 2,982
RR 1 1.4 1.7 2.0 2.3 2.6 3.0 3.6 4.4 6.8
65–69 5-year incidencea 533 788 951 1,105 1,265 1,445 1,660 1,941 2,383 3,714
RR 1 1.5 1.8 2.0 2.4 2.7 3.1 3.6 4.5 7.0
70–74 5-year incidencea 635 948 1,160 1,358 1,563 1,790 2,058 2,419 2,991 4,616
RR 1 1.5 1.8 2.1 2.5 2.8 3.2 3.8 4.7 7.3
75–79 5-year incidencea 681 1,077 1,326 1,578 1,827 2,119 2,462 2,954 3,671 5,785
RR 1 1.6 1.9 2.3 2.7 3.1 3.6 4.3 5.4 8.5
aFive-year incidence per 105 person-years adjusting for competing mortality risks. RR, relative risk.Available online http://breast-cancer-research.com/content/10/4/R55
Page 11 of 11
(page number not for citation purposes)
11. Colditz GA: The nurses' health study: a cohort of US women
followed since 1976.  J Am Med Womens Assoc 1995,
50:40-44.
12. Colditz GA, Hankinson SE: The Nurses' Health Study: lifestyle
and health among women.  Nat Rev Cancer 2005, 5:388-396.
13. Rich-Edwards JW, Corsano KA, Stampfer MJ: Test of the
National Death Index and Equifax Nationwide Death Search.
Am J Epidemiol 1994, 140:1016-1019.
14. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Ros-
ner B, Hennekens CH: Test of the National Death Index.  Am J
Epidemiol 1984, 119:837-839.
15. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE:
Risk factors for breast cancer according to estrogen and pro-
gesterone receptor status.  J Natl Cancer Inst 2004,
96:218-228.
16. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ,
Spiegelman D, Barbieri RL, Speizer FE: Plasma sex steroid hor-
mone levels and risk of breast cancer in postmenopausal
women.  J Natl Cancer Inst 1998, 90:1292-1299.
17. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA,
Stampfer MJ, Longcope C, Speizer FE: Alcohol, height, and adi-
posity in relation to estrogen and prolactin levels in postmen-
opausal women.  J Natl Cancer Inst 1995, 87:1297-1302.
18. Hankinson SE, London SJ, Chute CG, Barbieri RL, Jones L, Kaplan
LA, Sacks FM, Stampfer MJ: Effect of transport conditions on
the stability of biochemical markers in blood.  Clin Chem 1989,
35:2313-2316.
19. Rubin D: Multiple Imputation for Nonresponse in Surveys New
York: Wiley; 1987. 
20. Rosner B: Fundamentals of Biostatistics 6th edition. Belmont, CA:
Wadsworth; 2007. 
21. Pencina MJ, D' Agostino RBS, D' Agostino RBJ, Vasan RS: Eval-
uating the added predictive ability of a new marker: from area
under the ROC curve to reclassification and beyond.  Stat Med
2008, 27:157-172.
22. Rosner B, Glynn RJ: Power and sample size estimation for the
Wilcoxon rank sum test with application to comparisons of C
statistics from alternative prediction models.  Biometrics  in
press. 2008, May 28
23. Arias E: United States life tables, 2004.  Natl Vital Stat Rep 2007,
56:1-39.
24. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope
C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A,
Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV,
Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE,
Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri
S, Pala V, Venturelli E, et al.: Body mass index, serum sex hor-
mones, and breast cancer risk in postmenopausal women.  J
Natl Cancer Inst 2003, 95:1218-1226.
25. Bernstein L, Ross RK: Endogenous hormones and breast can-
cer risk.  Epidemiol Rev 1993, 15:48-65.
26. Lamar CA, Dorgan JF, Longcope C, Stanczyk FZ, Falk RT,
Stephenson HE Jr: Serum sex hormones and breast cancer risk
factors in postmenopausal women.  Cancer Epidemiol Biomar-
kers Prev 2003, 12:380-383.
27. Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA, Hoo-
ver RN: Serum hormone levels in relation to reproductive and
lifestyle factors in postmenopausal women (United States).
Cancer Causes Control 1998, 9:199-207.
28. Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ: Circu-
lating levels of sex hormones and their relation to risk factors
for breast cancer: a cross-sectional study in 1092 pre- and
postmenopausal women (United Kingdom).  Cancer Causes
Control 2001, 12:47-59.
29. Singletary KW, Gapstur SM: Alcohol and breast cancer: review
of epidemiologic and experimental evidence and potential
mechanisms.  JAMA 2001, 286:2143-2151.
30. Cook NR: Use and misuse of the receiver operating character-
istic curve in risk prediction.  Circulation 2007, 115:928-935.
31. Rockhill B, Kawachi I, Colditz GA: Individual risk prediction and
population-wide disease prevention.  Epidemiol Rev 2000,
22:176-180.
32. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA: Vali-
dation of the Gail et al. model of breast cancer risk prediction
and implications for chemoprevention.  J Natl Cancer Inst
2001, 93:358-366.
33. Wald NJ, Hackshaw AK, Frost CD: When can a risk factor be
used as a worthwhile screening test?  BMJ 1999,
319:1562-1565.
34. Tice JA, Miike R, Adduci K, Petrakis NL, King E, Wrensch MR: Nip-
ple aspirate fluid cytology and the Gail model for breast cancer
risk assessment in a screening population.  Cancer Epidemiol
Biomarkers Prev 2005, 14:324-328.